AU2000277557A1 - Methods of agonizing and antagonizing fabk - Google Patents

Methods of agonizing and antagonizing fabk

Info

Publication number
AU2000277557A1
AU2000277557A1 AU2000277557A AU7755700A AU2000277557A1 AU 2000277557 A1 AU2000277557 A1 AU 2000277557A1 AU 2000277557 A AU2000277557 A AU 2000277557A AU 7755700 A AU7755700 A AU 7755700A AU 2000277557 A1 AU2000277557 A1 AU 2000277557A1
Authority
AU
Australia
Prior art keywords
fabk
agonizing
antagonizing
methods
antagonizing fabk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000277557A
Inventor
Martin Brandt
Walter E. Dewolf Jr.
Paul M Keller
Arunbhai H. Patel
David J. Payne
Shannon L. Reed
Mark A. Seefeld
David G. Tew
Nicola G. Wallis
Joshua M. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of AU2000277557A1 publication Critical patent/AU2000277557A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2000277557A 2000-10-06 2000-10-06 Methods of agonizing and antagonizing fabk Abandoned AU2000277557A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/027628 WO2002031128A1 (en) 2000-10-06 2000-10-06 Methods of agonizing and antagonizing fabk

Publications (1)

Publication Number Publication Date
AU2000277557A1 true AU2000277557A1 (en) 2002-04-22

Family

ID=21741855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000277557A Abandoned AU2000277557A1 (en) 2000-10-06 2000-10-06 Methods of agonizing and antagonizing fabk

Country Status (4)

Country Link
EP (1) EP1330515A4 (en)
AU (1) AU2000277557A1 (en)
CA (1) CA2424987A1 (en)
WO (1) WO2002031128A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010881A (en) 1996-02-20 2000-01-04 Smithkline Beecham Corporation RibG
JP2000514308A (en) 1996-08-16 2000-10-31 スミスクライン・ビーチャム・コーポレイション Novel prokaryotic polynucleotides, polypeptides and uses thereof
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
US7033795B2 (en) 2000-10-06 2006-04-25 Affinium Pharmaceuticals, Inc. FabK variant
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US7056697B2 (en) 2000-10-06 2006-06-06 Affinium Pharmaceuticals, Inc. FabK variant
CA2519429C (en) * 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
WO2005005469A2 (en) 2003-07-11 2005-01-20 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
JP2007517056A (en) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド Pyrrole and pyrazole DAAO inhibitors
DK1828167T3 (en) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamide derivatives as antibiotic agents
WO2006008660A2 (en) * 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
RU2430913C2 (en) 2006-01-06 2011-10-10 Сепракор Инк. Cycloalkylamines as monoamine reuptake inhibitors
JP5438975B2 (en) 2006-01-06 2014-03-12 サノビオン ファーマシューティカルズ インク Tetralone monoamine reuptake inhibitor
DK2013835T3 (en) 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX2009012685A (en) 2007-05-31 2009-12-14 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK57999A3 (en) * 1996-12-05 2000-05-16 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
US6271000B1 (en) * 1996-12-13 2001-08-07 Eli Lilly And Company Streptococcus pneumoniae gene sequence mraY
JP4803935B2 (en) * 1999-10-08 2011-10-26 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FABI inhibitor

Also Published As

Publication number Publication date
EP1330515A4 (en) 2005-12-07
CA2424987A1 (en) 2002-04-18
EP1330515A1 (en) 2003-07-30
WO2002031128A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2000277557A1 (en) Methods of agonizing and antagonizing fabk
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU2001275737A1 (en) System and method of detecting events
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU2515000A (en) Pipe structure and method of manufacture
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU2001259200A1 (en) Method of brazing and article made therefrom
AU2001294549A1 (en) Process and intermediates
AU4819899A (en) Coupling half and method of making same
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002315225A1 (en) Fastener remover and method of use
AU5261701A (en) Method for purification of tetrafluoromethane and use thereof
AU2001237163A1 (en) Wastewater separator and method of using same
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2001280646A1 (en) Display and method of manufacture
AU2002310237A1 (en) Sponge-derived terpenoids and methods of use
AU2962400A (en) Cleaner composition and method of use thereof
AU2001261837A1 (en) Automatic configuration of equipment and software
AUPQ952100A0 (en) Membranes and method of manufacture thereof
AU2001280198A1 (en) Airway-specific trypsin-like enzymes and method of using the same
AU2001284651A1 (en) Secreted proteins and methods of using same
AU2001292468A1 (en) Methods and means of rna analysis
AU2000259049A1 (en) Histidyl-proline diketopiperazine and method of use
AU2001261785A1 (en) Vdup1 promoter and methods of use thereof